tbuckley/cabot-search huggingface dataset:
Tic disorders
Authors: E. Shapiro
Journal: JAMA (1981)

JIMMY'S mother is troubled. For the last few years her son has had strange and bizarre symptoms, and she cannot remember ever seeing another child behave the way he does. Jimmy was an average child until the age of 7 years, at which time his mother noted that he would often blink one eye out of synchrony with the other. She was told that this blinking was a nervous habit and was urged to ignore it. Unfortunately she could not, for other unusual "habits" began to appear. Within six months, Jimmy was uncontrollably twitching his nose, jerking his hand, and shrugging his shoulders. These mannerisms, while troublesome to Jimmy and his parents, were minor compared with those that followed: sniffing, throat clearing, barking and grunting noises, and finally, muffled words that sounded obscene. The tics subsided or went away completely for several months at a time. Because of Jimmy's continuing
Modeling Morphogenesis and Oncogenesis in Three-Dimensional Breast Epithelial Cultures
Authors: Christy Hebner, Valerie M. Weaver, Jayanta Debnath
Journal: Annual Review of Pathology Mechanisms of Disease (2007)

Three-dimensional (3D) epithelial culture systems recreate the cardinal features of glandular epithelium in vivo and represent a valuable tool for modeling breast cancer initiation and progression in a structurally appropriate context. 3D models have emerged as a powerful method to interrogate the biological activities of cancer genes and oncogenic pathways, and recent studies have poignantly illustrated their utility in dissecting the emerging role of tensional force in regulating epithelial tissue homeostasis. We review how 3D models are being used to investigate fundamental cellular and biophysical mechanisms associated with breast cancer progression that have not been readily amenable to traditional genetic or biochemical analysis.
Characterization studies on the cadmium-binding proteins from two species of New Zealand oysters.
Authors: M Nordberg, I Nuottaniemi, M G Cherian, G F Nordberg, T Kjellström, J S Garvey
Journal: Environmental Health Perspectives (1986)

Two different types of New Zealand oysters--Ostrea lutaria (OL) and Crassostrea glomerata (CG)--contained different concentrations of zinc, copper, and cadmium. OL oysters had 5.3 micrograms Cd/g, 3.4 micrograms Cu/g, 100 micrograms Zn/g; CG oysters had 1.4 micrograms Cd/g and 936 micrograms Zn/g. Both kinds of oysters were shown by gel filtration (G-75) to contain cadmium and zinc in fractions corresponding to a high molecular weight protein (corresponding to the size of albumin or larger) which was heat labile. OL oysters contained cadmium in fractions corresponding to a molecular weight of approximately 6500. The cadmium-binding protein in these fractions was heat-stable. This protein contained no detectable amounts of zinc and was not present in the CG oysters. Further purification by gel filtration (G-50) was performed to obtain a purer protein fraction. Isoelectric focusing of the protein obtained by G-50 filtration showed one main fraction of protein with a pI approximately 5.9 at approximately 13 degrees C. CG oysters contained cadmium and zinc in a polypeptide with low molecular weight (MW 1000). The cadmium-binding oyster proteins are minimally reactive in a competitive binding radioimmunoassay in comparison to the reactivity of a typical vertebrate metallothionein; the proteins may be metallothioneins, but, if so, they do not exhibit the principal determinants characteristic of vertebrate metallothioneins.
Shortening the duration of treatment for cervical tuberculous lymphadenitis
Authors: J.H van Loenhout-Rooyackers, R.J.F. Laheij, C Richter, A.L.M. Verbeek
Journal: European Respiratory Journal (2000)

The aim of the study was to determine the optimal duration of treatment for patients with tuberculous lymphadenitis. The Medline database was searched for relevant articles published between 1978-1997. Inclusion criteria were study populations of patients with predominantly cervical tuberculous lymphadenitis in whom the diagnosis had been confirmed bacteriologically and/or histologically, or was made probable by using clinical and laboratory markers. Treatment management had to include at least isoniazid, rifampicin and pyrazinamide and a follow-up of at least 12 months after the end of treatment. Patients with resistance to rifampicin and pyrazinamide and previous treatment for tuberculosis were excluded. The number of patients who relapsed after treatment was calculated. The study population in eight out of the 35 articles retrieved were suitable for analysis. Some concerned comparative studies. There were eight treatment schedules of 6 months9 duration and three schedules of 9 months9 duration. Treatment for 6 months resulted in a tuberculous lymphadenitis relapse rate of 13/422=3.3% (95% confidence interval: 1.7-5.5), with a mean follow-up of 31 months after completion of treatment. Treatment for 9 months resulted in a relapse rate of 3/112=2.7% (95% confidence interval: 0.6-7.8), with a mean follow-up of 20 months. Despite the limitations of the literature available, 6 months of therapy is probably sufficient for patients with tuberculous lymphadenitis.
Decade may be more than half over before acellular pertussis vaccines arrive on scene
Authors: C. Marwick
Journal: JAMA (1990)

IN SPITE of evidence that they are less reactogenic and confer long-standing immunity, the acellular pertussis vaccines are still a long way from reaching the American pediatrician. At least one speaker from the Sixth International Symposium on Pertussis (held at the National Institutes of Health [NIH], Bethesda, Md), Roger Bernier, MD, of the Centers for Disease Control, Atlanta, Ga, says it is unlikely that an acellular vaccine will be available before the mid-1990s. Bernier's point is that there has been no direct comparison between the acellular and whole-cell vaccines. Hence, he says, another trial is needed to ascertain the relative efficacy and safety of the acellular vaccines. This prediction was not seriously challenged. "I think it's going to be 4 or 5 years before we get there, although I hope it's sooner," comments John R. LaMontagne, MD, of the National Institute of Allergy and Infectious Diseases, part of the NIH.
Treatment.
Journal: JAMA (1907)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA (2013)

In a 2012 survey of 3897 randomly selected US physicians to assess physicians' perceived roles and responsibilities in addressing health care costs, Tilburt and colleagues found that the responding physicians accepted some responsibility to address health costs, but they were more likely to assign major cost-reduction responsibility to other groups including insurers, trial lawyers, hospitals and health systems, pharmaceutical and device manufacturers, and patients.The respondents expressed general agreement with several quality initiatives to reduce costs but reported less enthusiasm for cost-containment involving changes in payment models, such as eliminating fee-for-service payment.In an Editorial, Emanuel and Steinmetz discuss why physicians must take the lead in controlling health care costs.
Tolmetin-induced aseptic meningitis
Authors: G. B. Ruppert
Journal: JAMA (1981)

A 21-year-old woman with systemic lupus erythematosus (SLE) had meningismus, conjunctivitis, lymphadenopathy, and elevation of liver function values following ibuprofen therapy. All symptoms and laboratory value abnormalities resolved rapidly when the drug therapy was stopped. Two years later, a similar reaction occurred after taking tolmetin sodium. Fever, adenopathy, aseptic meningitis with a polymorphonuclear pleocytosis, and serum transaminase level elevations resolved rapidly after use of the drug was discontinued. The mechanism of this reaction to nonsteroidal antiinflammatory drugs in patients with SLE is not known. (<i>JAMA</i>1981;245:67-68)
The prognostic value of systemic inflammation in patients undergoing surgery for rectal cancer: Comparison of composite ratios and cumulative scores.
Authors: Ross Dolan, Stephen Thomas McSorley, James Hugh Park, Campbell SD Roxburgh, Paul G. Horgan, Donald C McMillan
Journal: Journal of Clinical Oncology (2018)

579 Background: Colorectal cancer is the second commonest cause of cancer death in Europe and North America with rectal cancer making up a third of this disease burden. Markers of the systemic inflammatory response (SIR) have been shown to be prognostic in cancer. These include ratio of different white blood cells/acute phase proteins such as NLR (neutrophil/lymphocytes), PLR (platelets/lymphocytes), LMR (lymphocytes/monocytes) and CAR (CRP/albumin) and cumulative prognostic scores such as NPS (Neutrophil Platelet Score)/mGPS (modified Glasgow Prognostic Score). The aim of the present study was to compare the prognostic value of SIR markers in patients undergoing surgery for rectal cancer. Methods: A prospectively maintained database of all patients undergoing elective curative rectal resection in our institution was examined. The SIR was measured by the ratios and scores NLR, PLR, LMR, CAR, NPS and mGPS using standard thresholds NLR (&gt;5), PLR (&gt;150), LMR (&lt;2.4), CAR (&gt;0.24), NPS (0, 1, 2) and mGPS (0, 1, 2). Statistical analysis was carried out in SPSS using ROC curve and Cox regression analysis for both cancer specific survival (CSS) and overall survival (OS). Results: Of the 393 patients included in the study, 237 (60%) were male, 91 (25.6%) had neoadjuvant therapy, 341 (87%) had open surgery, 285 (72.5%) had T3/4 disease and 155 (39.4%) and node positive disease. On ROC curve analysis, validated ratios and scores such as NLR (AUC: 0.534 95%CI 0.469-0.600), PLR (AUC: 0.526 95%CI 0.444-0.607), LMR (AUC: 0.574 95%CI 0.472-0.676), CAR (AUC: 0.551 95%CI 0.487-0.615), NPS (AUC: 0.578 95%CI 0.513-0.643) and mGPS (AUC: 0.571 95%CI 0.513-0.629) showed considerable similarities. On multivariate categorical analysis with TNM stage there was a significant relationship between CSS and NPS (HR: 2.09 95%CI 1.14-3.82, p=0.017), CAR &gt; 0.22 (HR: 1.64 95%CI 1.09-2.47, p=0.018) and mGPS (HR: 3.06 95%CI 1.71-5.47, p &lt; 0.001). Conclusions: The SIR as measured by a number of scores/ratios had prognostic value in patients with rectal cancer. Only the NPS and mGPS had prognostic value independent of TNM stage. These scores may be useful in stratifying treatment in patients with rectal cancer.
The IL-6R chain controls lung CD4+CD25+ Treg development and function during allergic airway inflammation in vivo
Authors: A. Doganci
Journal: Journal of Clinical Investigation (2005)

Due to an error in manuscript preparation, an incorrect shRNA sequence for IRS2 was published.The correct hairpin sequence is a 19-nt stretch beginning from nt 703 of the published IRS2 cDNA sequence (XM_357863).The oligonucleotides cloned into the U6 construct for the IRS2U6 adenovirus are as follows: tcgagGTGACGCTGCAGCTTATGAttcaagagaTCATAAGCTGCAGCGTCACttttt (forward) and ctagAAAAAGTGACGCTGCAGCTTATGAtctcttgaaTCATAAGCTGCAGCGTCACc (reverse).In addition, the shRNA cassettes were cloned into the adenoviral cosmid pAxcwit, which lacks a promoter, and not the cosmid pAxCAwtit, as published..
Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small cell lung cancer (NSCLC)
Authors: I. S. Grills, V. Mangona, R. Welsh, G. Chmielewski, E. McInerney, H. Ye, L. L. Kestin
Journal: Journal of Clinical Oncology (2009)

7516 Background: To compare clinical outcomes between lung stereotactic radiotherapy (SBRT) and wedge resection for stage I NSCLC. Methods: 112 cases of T1–2N0 NSCLC were treated with wedge resection (n=69) or image-guided lung SBRT (n=43) from 2/2003–8/2008. SBRT patients were treated on a phase II trial. All patients were ineligible for anatomic lobectomy; 93% undergoing SBRT were medically inoperable; 7% refused surgery. Mean FEV1 and DLCO were 1.58L and 13.9ml/min/mmHg for wedge cases vs 1.29L and 10.1ml for SBRT (p&lt;0.01, p&lt;0.01). Mean Charlson Co-morbidity Index and median age were 3 and 74y for wedge vs 4 and 77y for SBRT (p&lt;0.01, p=0.04). Patients were staged using CT, 18 FDG PET-CT, pulmonary function testing, and chemistries. SBRT patients had bone scan and brain MRI. Mediastinoscopies were performed for 28% of wedge cases vs.16% for SBRT (p=NS). SBRT was prescribed as 48 (T1) or 60 (T2) Gy in 4–5 fractions to the edge of the target volume. Adjuvant chemotherapy was given to 22% of SBRT vs12% of wedge patients (p=NS). Results: Median potential follow-up=2.3y. No significant differences were identified in local (LR), regional (RR), or locoregional recurrence (LRR), distant metastasis (DM), freedom from any failure (FFF), overall survival, or cause-specific survival between the two groups (Table); however, trends toward reduced LR and improved FFF were found with SBRT. Results excluding cases of synchronous primary tumors or pathologicalT4 (satellite lesion at wedge) are also shown, with FFF significantly better for SBRT. Multivariate analysis showed tumor grade to predict LR; LR to predict DM; LR and angiolymphatic invasion to predict RR and RR, (+)margin, FEV1, and pathologic diameter OS (p=0.06, p=0.08, p=0.01, p=0.04) in wedge cases. Conclusions: Both lung SBRT and wedge resection are reasonable treatment options for Stage I NSCLC patients ineligible for anatomic lobectomy. SBRT showed trends toward reduced LR and failure. Additional follow-up will be needed to verify durability of these findings. [Table: see text] No significant financial relationships to disclose.
Oxaliplatin (L-OHP) in combination with 5-fluorouracil (5-FU)/l-leucovorin (l-LV) on modified Roswell Park regimen as first-line treatment of advanced colorectal cancer (ACRC): A phase I/II study
Authors: Y. Miyata, K. Shirao, A. Ohtsu, N. Boku, Y. Tanigawara
Journal: Journal of Clinical Oncology (2004)

3705 Background: L-OHP has been established as a key drug for ACRC, and FOLFOX 4 is commonly used in Europe and the US. We conducted this trial to determine the recommended dose (RD) and evaluate safety and efficacy of L-OHP + weekly bolus 5-FU/l-LV as first-line treatment of ACRC. Methods: Inclusion criteria were unresectable ACRC, no prior chemotherapy, PS (ECOG) 0–2, age 20 - 75 years, measurable lesions, and adequate organ functions. L-OHP was administered over 2 hours (hrs) IV on days 1, and 15 with l-LV over 2 hrs IV and 5-FU IV bolus on days 1, 8, and 15 every 28 days. Doses of L-OHP and l-LV were fixed at 85 mg/m2 and 250 mg/m2 respectively, and that of 5-FU was escalated from 400 mg/m2 (level 1) to 500 mg/m2 (level 2). RD was determined in a formal phase I dose escalation manner, and safety and efficacy were evaluated according to NCI-CTC v2.0 and RECIST guidelines. Results: No dose-limiting toxicity (DLT) was observed at level 1 (n = 3), but at level 2 (n = 4), 3 patients (pts) experienced DLTs in the first cycles; grade (G) 3 thrombocytopenia, G4 neutropenia, and G2 neutropenia required treatment delay over 7 days. Level 1 was therefore determined as the RD, and 11 pts more were accrued at this dose. A total of 18 pts (14 at RD) were enrolled. Male /female = 11/7, PS 0/1/2 = 15/3/0, median age 63 years (range 37 - 73), colon/rectum = 14/4. Median number of cycles treated was 5.5. Peripheral neuropathy was observed in all 18 pts, but with no functional impairment. G3 toxicities at RD were as follows: neutropenia in 2 pts, hemoglobin decreased, lymphopenia in 1 pt each. Overall response rate was 61% (CR/PR/SD/PD=0/11/7/0). Median progression-free survival was 170 days. Conclusions: L-OHP + weekly bolus 5-FU/l-LV regimen was well tolerated. Efficacy and safety appear to be comparable to those of FOLFOX 4. (Supported by Yakult Honsha Co., Ltd.) No significant financial relationships to disclose.
American Journal of Digestive Diseases, New York
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Comment
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 17752: Does a Three-month “Blanking Period” Also Exist After the Second Session of Atrial Fibrillation Ablation?
Authors: Yuhi Fujimoto, Meiso Hayashi, Eiichiro Oka, Kanako Hagiwara, Kenta Takahashi, Ippei Tsuboi, Kenji Yodogawa, Yu-ki Iwasaki, Yasushi Miyauchi, Wataru Shimizu
Journal: Circulation (2015)

Background: The concept of a blanking period within three months after the first session of radiofrequency (RF) catheter ablation for atrial fibrillation (AF) is widely accepted, but it remains unclear whether this phenomenon is also observed after the second session. We tried to examine the presence of a post second session blanking period, and the factors related to this phenomenon. Methods: Among 549 consecutive patients who underwent an initial AF ablation, 134 (96 males, 63 ± 10 years) received a second ablation procedure, and were followed for 634 ± 421 days thereafter. The patient clinical background, laboratory data, ablation procedures during the second session, and arrhythmia recurrences defined as any episodes of atrial tachyarrhythmias lasting ≥30 seconds were analyzed. Arrhythmia recurrences were classified into two categories: those seen within and after the first three months post ablation, which were defined as early period recurrences (EPRs), and late period recurrences (LPRs), respectively. Results: EPRs and LPRs developed in 28 (21%) and 25 (19%) patients, respectively. Although an EPR was an independent predictor of an LPR (hazard ratio, 8.17; 95% confidence interval 2.97-22.48), 13 of the 28 patients with EPRs (46%) did not experience LPRs, supporting the concept of a blanking period. Compared to the patients with both EPRs and LPRs, those who experienced only EPRs had a higher left ventricular ejection fraction (LVEF) (63.1 ± 2.3 vs. 71.3 ± 1.5%, P=0.006) and lower serum brain natriuretic peptide (BNP) level before the ablation session (169 ± 47 vs. 55 ± 12 pg/ml, P=0.015). There were no significant differences in the clinical background, left atrial diameter, amount of RF energy delivered, ablation procedures, and serum C-reactive protein (CRP) concentration after the session between these two groups. Conclusion: A three-month blanking period was also recognized after the second session of AF ablation. This phenomenon was related to the better patient cardiac function indicated by the LVEF and serum BNP, but was not associated with other clinical and laboratory parameters, including CRP, and ablation procedures.
Archives of Physical Medicine and Rehabilitation, Chicago
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal